Cincinnati, OH and Redlands, CA - Schulman IRB, the industry-leading central IRB for customer service and technology, and iMedRIS Data Corporation, the fastest growing technology provider for optimizing research compliance and administration software, are pleased to announce their partnership to provide research organizations with integrated technology, consulting and IRB review services.
Rather than contracting with multiple disparate service providers, research organizations and institutions can now work with a single organization for IRB review services, research management technology, and good clinical practice (GCP) and human research protections (HRP) consulting services.
“This partnership offers unparalleled service integration for ultimate ease of use,” said Michael Woods, President and CEO at Schulman IRB. “Schulman is delighted to now be able to offer clients the industry’s most flexible and user friendly research management tools available.”
“iMedRIS and Schulman share the same high standards of customer service and support, and we are excited to share Schulman’s services with our clients,” said William Schroeder, CEO at iMedRIS. “This represents two of the research community’s most trusted partners coming together to provide an integrated service package of unprecedented opportunities.”
This integration reflects the first phase in iMedRIS’ and Schulman IRB’s partnership. The two organizations will continue to evaluate their service offerings to find additional ways that clients can benefit from the collaboration.
About iMedRIS
iMedRIS’ primary focus on client satisfaction and success has made the company a leader in research software solutions. Through iRIS, iMedRIS has been able to enhance its principles and foundation as the fastest growing small business within the industry to emerge as the preferred integrated Research Information Software provider. Through the iRIS system’s scalable configurations and enhanced process of improvement, the capability to process electronic submissions has empowered researchers to be more accurate and efficient. These established principles and focus on institutional requirements have enabled iMedRIS to maintain its mission and goals in order to provide the research community with state of the art software and enhance institutional research programs.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.